[29 April 2013]
Products Affected - Description
Bupivacaine 0.25% with epinephrine
Bupivacaine 0.25% with epinephrine 1:200,000 injection, Hospira
50 mL vial, multi-dose (NDC 00409-9043-01)
Bupivacaine 0.5% with epinephrine
Bupivacaine 0.5% with epinephrine 1:200,000 injection, Hospira
50 mL vial, multi-dose (NDC 00409-9046-01)
30 mL vial, preservative-free (NDC 00409-9045-17)
Reason for the Shortage
- APP had Sensorcaine with epinephrine on shortage due to increased demand for the product.
- Hospira has bupivacaine with epinephrine and Marcaine with epinephrine on shortage due to manufacturing delays.
Available Products
Bupivacaine 0.25% with epinephrine
Bupivacaine 0.25% with epinephrine 1:200,000 injection, Hospira
10 mL vial, preservative-free (NDC 00409-9042-01)
30 mL vial, preservative-free (NDC 00409-9042-17)
Marcaine 0.25% (with epinephrine 1:200,000) injection, Hospira
10 mL vial, preservative-free (NDC 00409-1746-10)
30 mL vial, preservative-free (NDC 00409-1746-30)
50 mL vial, multi-dose (NDC 00409-1752-50)
Sensorcaine 0.25% (with epinephrine 1:200,000), APP
10 mL vial, preservative-free (NDC 63323-0468-17)
30 mL vial, preservative-free (NDC 63323-0468-37)
50 mL vial, multi-dose (NDC 63323-0461-57)
Bupivacaine 0.5% with epinephrine
Bupivacaine 0.5% with epinephrine 1:200,000 injection, Hospira
10 mL vial, preservative-free (NDC 00409-9045-01)
Marcaine 0.5% with epinephrine 1:200,000 injection, Hospira
10 mL vial, preservative-free (NDC 00409-1749-10)
30 mL vial, preservative-free (NDC 00409-1749-29)
50 mL vial, multi-dose (NDC 00409-1755-50)
Sensorcaine 0.5% with epinephrine 1:200,000, APP
10 mL vial, preservative-free (NDC 63323-0462-17)
30 mL vial, preservative-free (NDC 63323-0462-37)
30 mL vial, preservative-free, sterile pack (NDC 63323-0462-31)
50 mL vial, multi-dose (NDC 63323-0463-57)
Bupivacaine 0.75% with epinephrine
Sensorcaine 0.75% with epinephrine 1:200,000, APP
30 mL vial, preservative-free (NDC 63323-0460-37)
Estimated Resupply Dates
Bupivacaine 0.25% with epinephrine
- Hospira has bupivacaine 0.25% with epinephrine 50 mL multi-dose vials on back order and the company estimates a release date of May 2013.
Bupivacaine 0.5% with epinephrine
- Hospira has bupivacaine 0.5% with epinephrine 50 mL multi-dose vials and 30 mL preservative-free vials on back order and the company estimates a release date of June 2013.
Related Shortages
Updated
April 29, 2013; March 29, 2013; March 5, 2013; February 22, 2013; January 28, 2013; January 2, 2013; December 18, 2012; November 28, 2012; November 9, 2012; October 22, 2012; October 8, 2012; September 24, 2012; August 22, 2012; July 25, 2012; June 28, 2012; June 5, 2012; May 17, 2012; April 16, 2012; March 27, 2012; March 7, 2012; February 22, 2012; February 8, 2012; January 25, 2012; January 5, 2012; December 21, 2011; December 7, 2011; November 16, 2011; October 31, 2011; October 27, 2011; October 12, 2011; September 21, 2011; August 24, 2011; July 28, 2011; July 13, 2011; June 30 2011; June 23, 2011; June 1, 2011; May 23, 2011; April 28, 2011; April 7, 2011; March 24, 2011; March 15, 2011; March 10, 2011; February 4, 2011; January 25, 2011; January 21, 2011; January 10, 2011; December 20, 2010; December 6, 2010; October 19, 2010, University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT.
Disclaimer
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins